Naineni Rohini, Ravi Vishali, Subbaraya Dwijendra Kocherlakota, Prasanna Jammula Surya, Panthula Veerendranath Reddy, Koduganti Rekha Rani
Reader, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
Senior Lecturer, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences and Research Centre , Hyderabad, Telangana, India .
J Clin Diagn Res. 2016 Aug;10(8):ZC113-7. doi: 10.7860/JCDR/2016/20965.8365. Epub 2016 Aug 1.
Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (β-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like β-TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling.
The aim of the this study was to evaluate the bone formation potential of 400μg ALN delivered in β-TCP in the treatment of periodontal intra-osseous defects.
Thirty patients with periodontal defects were randomly assigned to 400μg ALN + β-TCP + Saline (test) group and β-TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs.
Mean measurements in the ALN test group for CAL gain (3.4 ± 0.74 mm), PD reduction (4.33 ± 0.82 mm), LBG (2.88 ± 0.88 mm), and %BF (51.98 ± 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 ± 0.86 mm), PD reduction (3.20 ± 1.15 mm), LBG (1.70 ± 0.39 mm), and %BF (30.35 ± 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 ± 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 ± 0.40 mm) in the control group.
400μg ALN combined with β-TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to β-TCP alone.
阿仑膦酸盐（ALN）是一种氨基双膦酸盐，可抑制破骨细胞的骨吸收，还能刺激骨生成。β-磷酸三钙（β-TCP）是一种骨传导性移植材料，为骨形成提供支架，也是生长因子和抗生素广泛使用的药物递送载体。像β-TCP这样的药物递送载体，通过药物的特定局部递送、最佳释放特性和易于操作来提高药物的效力。
本研究的目的是评估在β-TCP中递送400μg阿仑膦酸盐治疗牙周骨内缺损的骨形成潜力。
30例牙周缺损患者被随机分为400μg阿仑膦酸盐+β-TCP+生理盐水（试验）组和β-TCP+生理盐水（活性对照）组。从基线、3个月和6个月的记录中评估临床附着水平（CAL）增加、探诊深度（PD）减少、术后牙龈退缩（GR）等临床参数。从基线和6个月的X线片评估线性骨生长（LBG）、骨填充百分比（%BF）和牙槽嵴高度变化（ACH）等影像学参数。
与对照组CAL增加（2.20±0.86mm）、PD减少（3.20±1.15mm）、LBG（1.70±0.39mm）和%BF（30.35±6.88%）的平均测量值相比，阿仑膦酸盐试验组CAL增加（3.4±0.74mm）、PD减少（4.33±0.82mm）、LBG（2.88±0.88mm）和%BF（51.98±15.84%）的平均测量值显著更高，p值<0.05。阿仑膦酸盐试验组有轻度牙槽嵴附着（0.32±0.68mm），对照组有轻度牙槽嵴吸收（-0.24±0.40mm）。
与单独使用β-TCP相比，400μg阿仑膦酸盐与β-TCP骨移植材料联合使用在改善软组织参数、抑制牙槽嵴吸收和促进骨形成方面有效。
